See our management structure

Chief Executive Officer

Mr. Léon J.A. Spijkers, PhD

Cofounded Korecyte Bio in 2023. Leon has over 15 years’ experience in Life Sciences and Pharma management, R&D and business development. Léon founded a biotech interim-management and consultancy firm via which he held several client positions as Chief Business Officer and BD Director. He worked with biotech start-up and scale-up clients, co-founded a biotech company from incorporation towards clinical stage and accumulated a significant track record in evolving ventures to the next phase. He holds a PhD in molecular cell biology, is a registered pharmacologist and holds a certificate in business administration essentials from the London School of Economics.

Korecyte Bio is an international biotech startup based between the Netherlands and United Kingdom that was established in 2023. Our mission is to develop next-generation CAR-T cellular immunotherapies

Chief Scientific Officer

Dr James N. Arnold, DPhil

Cofounded Korecyte Bio in 2023. James has over 20 years of research experience in the field of Immunology. He acquired his DPhil at the University of Oxford and conducted his Postdoctoral research at the University of Cambridge. James established the Tumour Immunology Group at King’s College London in 2012 and has dedicated his team there to developing new immunotherapy strategies for treating cancer. James has sat on Grant Committees for major UK cancer charities and currently holds the academic grade of Reader in Tumour Immunology and Immunotherapy at King’s College London. James is a co-inventor of HypoxiCAR Immunotherapy.

Chief Financial Officer

Mr. Simi Nehra, BA, ACA, CF

CFO for Korecyte Bio since 2024. Simi is a Chartered Accountant with over 20 years’ experience. As an experienced CFO, he has led the growth of companies ranging from start-ups to multinationals and he has supported several Healthcare and Life Sciences companies. With his hands-on approach, he has been involved in several scale-up companies from managing KPIs, driving M&A transactions and capital raising processes, setting up financial and reporting systems, managing working capital, budgeting and cash flow forecasting. Previously, he was Head of Mergers and Acquisitions (M&A) for KPMG in the Middle East region, where he provided buy side, sell side and capital raising solutions to private equity (PE) and corporate clients. Prior to joining KPMG, Simi was a Corporate Finance Partner at Grant Thornton. Simi secured the accolade of the Mergermarket ‘2018 M&A Middle East winner for healthcare’.

Mr. Léon J.A. Spijkers, PhD

Dr James N. Arnold, DPhil

Mr. Simi Nehra, BA, ACA, CF

Interested in Korecyte Bio? Contact us or read more about our scientific approach.